(Z)-epi-beta-Santalol is one of the fragrance-defining sesquiterpenols of true sandalwood oil and a recurring secondary santalol in the AromaForge sandalwood records. The strongest live evidence supports identity, occurrence, and biosynthesis, including a heartwood-specific sandalwood paper that explicitly names this isomer among the key fragrance outputs of a stereo-selective P450. Standalone pharmacology and safety evidence for the purified isomer are limited, so this archive record should emphasize chemistry and sandalwood-authentication relevance rather than consumer benefit claims.
Chemical identity and composition
NIST provides an exact entry for (Z)-epi-beta-Santalol under CAS 79081-90-6 and also cross-links the same structure through a synonym page titled Santalol, E-cis,epi-beta- with CAS 14490-17-6, so registry-number handling in public databases is not perfectly uniform. PubChem and related synonym sources also connect epi-beta-santalol naming to beta-santalol records. In the local archive, this exact ID is used in sandalwood profiles where it sits around 3% to 4% as a secondary sesquiterpenol below alpha- and beta-santalol.
Aroma and practical use
- Use the recorded woody, soft, creamy, sandalwood descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2016 Plant Journal paper reported that a heartwood-expressed sandalwood P450, SaCYP736A167, stereo-selectively produces (Z)-epi-beta-santalol together with other fragrance-defining sandalwood sesquiterpenols, directly supporting this constituent's biosynthetic identity.
This is the strongest exact-isomer source located in this pass because it names the compound explicitly and ties it to the final biosynthetic step of sandalwood fragrance formation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2004 comprehensive two-dimensional GC study included epi-beta-santalol among the representative components used for high-resolution characterization of West Australian sandalwood oil.
This supports analytical importance and authentication relevance rather than isolated bioactivity.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2012 Journal of Economic Entomology study reported repellency of sandalwood oil against Tetranychus urticae and quantified epi-beta-santalol in the oil, but attributed the activity to santanol as a mixture rather than to isolated (Z)-epi-beta-santalol alone.
This is usable mixture-level context but not proof of a purified-constituent effect.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific RIFM safety assessment, IFRA restriction, or human tolerability study was verified for isolated (Z)-epi-beta-santalol in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Santalol-group corroboration (not isomer-specific): the EU SCCS Australian sandalwood tier II human health assessment categorizes Australian sandalwood oil as an established contact allergen in humans due to santalol content, with patch-test positive rates of 0.0071-1.53% at up to 10% concentration and 1.5% positivity in a 6-year patch-test study; a separate RIFM-linked sandalwood oil safety assessment (Api, Food and Chemical Toxicology, 2007) reports low acute oral/dermal toxicity but occasional irritation or sensitization reports in humans. This supports the existing sensitizing:true flag at the santalol-family level but does not establish an isomer-specific dermal limit for (Z)-epi-beta-santalol.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Because the accessible activity literature is mixture-level or biosynthetic rather than purified-dose human research, benefit-facing copy should avoid repellent, anti-inflammatory, or therapeutic claims for the isolated constituent.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Public registry records for this isomer show some alias and CAS variation across databases, so identity checks should prioritize structure and exact stereochemical naming rather than one registry number alone.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
alpha-SantalolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vivo nonhuman · effect
No source citation attached.
Read alpha-Santalol report →How the effects were investigated
stereoselective_p450_biosynthesis
A sandalwood heartwood study characterized SaCYP736A167 as a multi-substrate P450 that stereo-selectively produces (Z)-epi-beta-santalol along with other key sandalwood sesquiterpenols.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- No isolated (Z)-epi-beta-santalol human clinical literature was verified in this pass.
- The accessible literature is dominated by biosynthesis and analytical occurrence rather than dedicated pharmacology or toxicology studies.
- Public database handling of this isomer's CAS numbers and synonym mapping is not fully uniform.
- The RIFM santalol safety assessment (CAS 11031-45-1) covers mixed/pooled santalol, not this specific (Z)-epi isomer, so no isomer-specific numeric dermal limit could be verified; the previous 20% placeholder had no traceable citation and has been removed.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.